Publicaties
, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother. 2014 Apr;15(5):589-92.
, van Leeuwen BL, Hoekstra HJ. Surgical emergencies in oncology. Cancer Treat Rev. 2014 Sep;40(8):1028-36.
, Rashid OM, Zager JS. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1355-64
, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014 Dec;15(18):2629-39.
Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, , Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar;5(3):264-73
Ahmed KA, Freilich JM, , Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol. 2015 Mar;122(1):121-6
Speijers MJ, Bastiaannet E, , Suurmeijer AJ, Hoekstra HJ. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015 Sep;22(9):2978-87.
<0.1 mm) sentinel lymph node metastases. Ann Surg Oncol. 2015 Sep;22(9):2972-7 , Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (
Current management of surgical oncologic emergencies. PLoS One. 2015;10(5):e0124641.
, Bastiaannet E, van Leeuwen BL, Hoekstra HJSpeijers MJ, Bastiaannet E, Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015;22(9):2978-87.
, Suurmeijer AJ, Hoekstra HJ.Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases. Ann Surg Oncol. 2015 Sep;22(9):2972-7.
, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016 Feb;26(1):83-7.
, Bastiaannet E, van Leeuwen BL, Hoekstra HJ.Factors Associated with Short-Term Mortality After Surgical Oncologic Emergencies. Ann Surg Oncol. 2016;23(6):1803-14
The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol. 2016;42(4):545-51.
, Hoekstra HJ, Bastiaannet E, Muller Kobold AC, Kruijff S, Wevers KP., Niebling MG, Kobold AC, Hoekstra HJ, Kruijff S, Wevers KP. Adipocytes in venipunctures cause falsely elevated S-100B serum values. Clin Chem Lab Med. 2016;54(8):e235-7.
, Speijers MJ, Bastiaannet E, Hoekstra HJ. Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.Cancer Treat Rev. 2016; 45:120-8.
, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Ann Surg Oncol. 2016;23(9):2762-71.
, Ferguson PC, Wunder JS, Griffin A, Hoekstra HJ, Bagher S, Zhong T, Hofer SO, O’Neill AC. Can the ACS-NSQIP surgical risk calculator predict post-operative complications in patients undergoing flap reconstruction following soft tissue sarcoma resection? J Surg Oncol. 2016;114(5):570-575.
Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control. 2016; 23(1):12-20. Review.
, Rashid OM, Sarnaik AA, Zager JS.BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016;26(1):83-7.
, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT.Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res. 2017t;27(5):457-462.
Read RL, Emmett L, Thompson JF, Nieweg OE.Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control and survival. J Surg Oncol. 2018 ;117(3):434-442
, Musters AH, Geertzen JHB, van Leeuwen BL, Hoekstra HJ, Been LB.Verstijnen J, , Hoekstra HJ, Kruijff S, Ten Tije AJ, Louwman WJ, Bastiaannet E, Stuiver MM. Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands. Surg Oncol. 2017; 26:431-437.
, Ferguson PC, Wunder JS, Griffin AM, Hoekstra HJ, Liu X, Hofer SOP, O’Neill AC. , Hoekstra-Weebers JEHM, van Leeuwen BL, Hoekstra HJ.A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma. Eur J Surg Oncol. 2017;43(9):1753-1759.
, Wevers KP, Murali R, Kruijff S, Hoekstra HJ, Bastiaannet E.Holtkamp LHJ, Read RL, Emmett L, Thompson JF, Nieweg OE. Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res. 2017;27(5):457-462.
Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA. Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases. Ann Surg Oncol. 2017 Dec (Suppl 3):660
, Hoekstra HJ, Song W, Suurmeijer AJH, Been LB. , Been LB, Hoekstra HJ, Suurmeijer AJH, Boellaard R, Brouwers AH. , Ubbels JF, Slump J, Huijing MA, Bastiaannet E, Pras E, Hoekstra HJ, Been LB. , Hofer SOP, Ferguson PC, Wunder JS, Griffin AM, Hoekstra HJ, Bastiaannet E, O’Neill AC. , Seinen JM, Pras E, Brouwers AH, van Ginkel RJ, van Leeuwen BL, Suurmeijer AJH, Been LB, Hoekstra HJ. , Bastiaannet E, Halka A, Hoekstra HJ, Ferguson PC, Wunder JS, Hofer SOP, O’Neill AC.O. M. Vrielink, M. Faut, E. A. Deckers, B. L. van Leeuwen, L. B. Been. Evaluation of the videoscopic inguinal lymphadenectomy in melanoma patients. Eur. J. Surg. Oncol 2019;45:1712-16.
Deckers EA, Wevers KP, Muller Kobold AC, S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients. J Surg Oncol. 2019;120(6):1031-1037.
, Vrielink OM, van Ginkel RJ, Been LB, van Leeuwen BL, Hoekstra HJ, Kruijff S. , Wj Louwman M, Kruijff S, Hoekstra HJ. , Muller Kobold AC, Bastiaannet E, Kruijff S, Hoekstra HJ, Wevers KP.Deckers EA, Hoekstra-Weebers JEHM, The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB-IIC Patients-Results After 3 Years. Ann Surg Oncol. 2020;27(5):1407-1417.
, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. , Kruijff S, Brouwers AH, van der Steen K, Hoekstra HJ, Thompson JF, Vállez García D, Wevers KP.Francken AB, Hoekstra-Weebers JEHM, ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified. Ann Surg Oncol. 2020 May;27(5):1418-1419
, Hoekstra HJ.M. R. Jansen, O. M. Vrielink , M. Faut, Eric A. Deckers, L. B. Been and B. L. van Leeuwen. One-Year Morbidity Following Videoscopic Inguinal Lymphadenectomy for Stage III Melanoma. Cancers 2021; 13(6):1450.
Moncrieff MD, Bastiaannet E, Underwood B, Francken AB, Garioch J, Damude S, Heaton M, Deckers EA, Patel N, Hoekstra-Weebers JE, Hoekstra HJ. Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial.Ann Surg. 2022;276(4):e208-e216.
Deckers EA, Louwman MW, Kruijff S, Hoekstra HJ. Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. Melanoma Manag. 2020 Mar 30;7(1):MMT38.
Deckers EA, Wevers KP, Muller Kobold AC, Damude S, Vrielink OM, van Ginkel RJ, Been LB, van Leeuwen BL, Hoekstra HJ, Kruijff S. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients. J Surg Oncol. 2019; 120(6):1031-1037.
Deckers EA, Kruijff S, Brouwers AH, van der Steen K, Hoekstra HJ, Thompson JF, Vállez García D, Wevers KP. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. Eur J Surg Oncol. 2020 Nov;46(11):2147-2153.
Ipenburg NA, Lo SN, Vilain RE, Holtkamp LHJ, Wilmott JS, Nieweg OE, Thompson JF, Scolyer RA. The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. J Am Acad Dermatol. 2020 Apr;82(4):910-919.
Holtkamp LHJ, Chakera AH, Fung S, Stretch JR, Saw RPM, Lee K, Ch’ng S, Gonzalez M, Thompson JF, Emmett L, Nieweg OE. Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Res. 2020; 30(4):358-363.
Nijhuis AAG, Santos Filho IDAO, Holtkamp LHJ, Uren RF, Thompson JF, Nieweg OE. Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis. Ann Surg Oncol. 2020; 27(2):561-568.
Jutten E, Kruijff S, Francken AB, Lutke Holzik MF, van Leeuwen BL, van Westreenen HL, Wevers KP. Surgical treatment of anorectal melanoma: a systematic review and meta-analysis. BJS Open. 2021; 5(6):zrab107.
Jutten E, Kruijff S, Francken AB, Lutke Holzik MF, van Leeuwen BL, van Westreenen HL, Wevers KP. Author response to: Surgical treatment of anorectal melanoma: a systematic review and meta-analysis. BJS Open. 2022; 6(1):zrac016.
Holtkamp LHJ, Lo S, Drummond M, Thompson JF, Nieweg OE, Hong AM. Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma. Clin Oncol (R Coll Radiol). 2023;35(1):e85-e93.
Holtkamp LHJ, Lo SN, Thompson JF, Spillane AJ, Stretch JR, Saw RPM, Shannon KF, Nieweg OE, Hong AM. Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection. J Surg Oncol. 2023 :128(1):97-104
Proefschriften
. Surgical Oncologic Emergencies. Decision Making and Clinical Outcome. RUG 21-09-2015
Developments in the treatment of advanced melanoma. RUG 22-11-2017
The role of reconstructive surgery in the treatment of soft tissue sarcomas. 24-09- 2018
Localized extremity soft tissue sarcoma: towards a patient-tailored approach. RUG 08-10-2018
Melanoma New Insights in Follow-up & Staging. RUG 28-11-2018
Melanoma; The Impact of Staging on Treatment, Prognosis & Follow-up. RUG, 20-04-2020
Stage III melanoma, a heterogeneous group of patients. Aspects of diagnosis, staging and treatments. RUG 15-04-2024